• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Long-term follow-up after deferring angioplasty in asymptomatic patients with moderate noncritical in-stent restenosis.对无症状的中度非严重支架内再狭窄患者延迟血管成形术后的长期随访。
Clin Cardiol. 2001 Aug;24(8):551-5. doi: 10.1002/clc.4960240806.
2
Immediate results and long-term clinical outcome of patients with unprotected distal left main restenosis: the CORPAL registry (Córdoba and Las Palmas).无保护左主干病变再狭窄患者的即刻结果和长期临床结局:CORPAL 注册研究(科尔多瓦和拉斯帕尔马斯)。
JACC Cardiovasc Interv. 2014 Feb;7(2):212-221. doi: 10.1016/j.jcin.2013.06.017. Epub 2014 Jan 15.
3
Efficacy of drug-eluting stents for treating in-stent restenosis of drug-eluting stents (from the Korean DES ISR multicenter registry study [KISS]).药物洗脱支架治疗药物洗脱支架内再狭窄的疗效(来自韩国 DES ISR 多中心注册研究[KISS])。
Am J Cardiol. 2012 Mar 1;109(5):607-13. doi: 10.1016/j.amjcard.2011.10.014. Epub 2011 Dec 14.
4
A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent).药物洗脱球囊与依维莫司洗脱支架治疗金属裸支架内再狭窄的随机对照研究:RIBS V 临床试验(金属裸支架内再狭窄:紫杉醇洗脱球囊与依维莫司洗脱支架)。
J Am Coll Cardiol. 2014 Apr 15;63(14):1378-86. doi: 10.1016/j.jacc.2013.12.006. Epub 2014 Jan 8.
5
A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis.支架内再狭窄患者重复支架置入术与球囊血管成形术的随机对照研究。
J Am Coll Cardiol. 2003 Sep 3;42(5):796-805. doi: 10.1016/s0735-1097(03)00852-0.
6
Clinical and procedural predictors of suboptimal outcome after the treatment of drug-eluting stent restenosis in the unprotected distal left main stem: the Milan and New-Tokyo (MITO) registry.药物洗脱支架再狭窄治疗后未保护的左主干远端的临床和操作预测因素:米兰和新东京(MITO)登记处。
Circ Cardiovasc Interv. 2012 Aug 1;5(4):491-8. doi: 10.1161/CIRCINTERVENTIONS.111.964874. Epub 2012 Jul 31.
7
Safety and efficacy of limus-eluting stents and balloon angioplasty for sirolimus-eluting in-stent restenosis.雷帕霉素洗脱支架和球囊血管成形术治疗雷帕霉素洗脱支架内再狭窄的安全性和有效性。
Cardiovasc Revasc Med. 2015 Mar;16(2):84-9. doi: 10.1016/j.carrev.2015.01.004. Epub 2015 Jan 29.
8
Combined cutting balloon angioplasty and intracoronary beta radiation for treatment of in-stent restenosis: clinical outcomes and effect of pullback radiation for long lesions.
Catheter Cardiovasc Interv. 2002 Nov;57(3):325-9. doi: 10.1002/ccd.10328.
9
Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter.紫杉醇涂层球囊导管治疗冠状动脉支架内再狭窄的长期随访。
JACC Cardiovasc Interv. 2012 Mar;5(3):323-30. doi: 10.1016/j.jcin.2012.01.008.
10
Treatment of drug-eluting stents in-stent restenosis with paclitaxel-coated balloon angioplasty: Insights from the French "real-world" prospective GARO Registry.使用紫杉醇涂层球囊血管成形术治疗药物洗脱支架内再狭窄:来自法国“真实世界”前瞻性GARO注册研究的见解。
Int J Cardiol. 2016 Jan 15;203:690-6. doi: 10.1016/j.ijcard.2015.11.031. Epub 2015 Nov 6.

引用本文的文献

1
Restenosis following percutaneous coronary arterial intervention: what should the clinician do in order to identify and treat this complication?经皮冠状动脉介入治疗后的再狭窄:临床医生应如何识别和治疗这一并发症?
Curr Cardiol Rep. 2004 Nov;6(6):391-2. doi: 10.1007/s11886-004-0043-6.

本文引用的文献

1
Does angiography six months after coronary intervention influence management and outcome? Benestent II Investigators.冠状动脉介入治疗六个月后进行血管造影会影响治疗管理及预后吗?贝内斯特II研究组。
J Am Coll Cardiol. 1999 Nov 1;34(5):1507-11. doi: 10.1016/s0735-1097(99)00380-0.
2
Clinical and angiographic predictors of recurrent restenosis after percutaneous transluminal rotational atherectomy for treatment of diffuse in-stent restenosis.经皮腔内旋磨术治疗弥漫性支架内再狭窄后再发再狭窄的临床及血管造影预测因素
Am J Cardiol. 1999 Mar 15;83(6):862-7. doi: 10.1016/s0002-9149(98)01074-1.
3
Rotational atherectomy for in-stent restenosis: acute and long-term results of the first 100 cases.冠状动脉内斑块旋切术治疗支架内再狭窄:首批100例患者的急性和长期结果
J Am Coll Cardiol. 1998 Nov;32(5):1358-65. doi: 10.1016/s0735-1097(98)00382-9.
4
Impact of routine angiographic follow-up after angioplasty.血管成形术后常规血管造影随访的影响。
Am Heart J. 1998 Oct;136(4 Pt 1):613-9. doi: 10.1016/s0002-8703(98)70007-9.
5
Asymptomatic restenosis: should we (re)intervene? An unresolved dilemma.无症状性再狭窄:我们应该(再次)干预吗?一个尚未解决的困境。
Am Heart J. 1998 Oct;136(4 Pt 1):576-7. doi: 10.1016/s0002-8703(98)70025-0.
6
Immediate and long-term outcomes of rotational atherectomy versus balloon angioplasty alone for treatment of diffuse in-stent restenosis.旋磨术与单纯球囊血管成形术治疗弥漫性支架内再狭窄的即刻和长期疗效
Am J Cardiol. 1998 Jul 15;82(2):140-3. doi: 10.1016/s0002-9149(98)00292-6.
7
Remodeling of in-stent neointima, which became thinner and transparent over 3 years: serial angiographic and angioscopic follow-up.
Circulation. 1998 May 26;97(20):2003-6. doi: 10.1161/01.cir.97.20.2003.
8
Chronic arterial responses to stent implantation: a serial intravascular ultrasound analysis of Palmaz-Schatz stents in native coronary arteries.支架植入后的慢性动脉反应:对天然冠状动脉中Palmaz-Schatz支架的系列血管内超声分析
J Am Coll Cardiol. 1996 Nov 1;28(5):1134-9. doi: 10.1016/S0735-1097(96)00278-1.
9
Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study.支架内再狭窄的模式与机制。一项血管内超声系列研究。
Circulation. 1996 Sep 15;94(6):1247-54. doi: 10.1161/01.cir.94.6.1247.
10
Three-year follow-up after implantation of metallic coronary-artery stents.
N Engl J Med. 1996 Feb 29;334(9):561-6. doi: 10.1056/NEJM199602293340903.

对无症状的中度非严重支架内再狭窄患者延迟血管成形术后的长期随访。

Long-term follow-up after deferring angioplasty in asymptomatic patients with moderate noncritical in-stent restenosis.

作者信息

Lee J H, Lee C W, Park S W, Hong M K, Kim J J, Rhee K S, Park S J

机构信息

Department of Medicine, Asan Medical Center, University of Ulsan, Seoul, Korea.

出版信息

Clin Cardiol. 2001 Aug;24(8):551-5. doi: 10.1002/clc.4960240806.

DOI:10.1002/clc.4960240806
PMID:11501607
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6654981/
Abstract

BACKGROUND

Many patients with in-stent restenosis (ISR) are angina-free, but the optimal treatment for these patients remains uncertain.

HYPOTHESIS

In cases with asymptomatic moderate noncritical ISR. deferral of the intervention may be safe and associated with favorable clinical outcome.

METHODS

We evaluated the long-term clinical outcome of asymptomatic patients (Group 1, n = 98) with moderate noncritical ISR (< 70% diameter stenosis) after intervention was deferred, and compared it with that of patients (Group 2, n = 655) without restenosis. After repeat angioplasty was deferred, all patients were treated medically and later underwent angioplasty only in the case of clinical recurrence.

RESULTS

Baseline characteristics were similar between the two groups. Clinical follow-up was available in all patients at 26.3+/-15.9 months. Twenty patients died during the follow-up: 1 in Group 1 and 19 in Group 2. Target lesion revascularization was performed in 3 patients in Group 1 and 11 patients in Group 2 during follow-up (p = NS), and new lesion revascularization in 2 patients in Group 1 and 27 patients in Group 2 (p = NS). Event-free survival rate (cardiac death, nonfatal myocardial infarction, repeat revascularization) was 86.7+/-6.1% in Group 1 and 84.8+/-2.2% in Group 2 at the end of follow-up (p = NS). Major adverse cardiac events were only associated with the presence of diabetic mellitus (hazards ratio 2.65, 95% confidence interval [CI] 1.48-4.73, p<0.01). The percentage of patients receiving antianginal medication was similar between the two groups at the end of the study (p = NS).

CONCLUSIONS

Asymptomatic patients with moderate noncritical ISR have a good prognosis and similar clinical outcome as those without ISR, suggesting that it may be safe to defer repeat angioplasty in these patients until angina recurrence.

摘要

背景

许多支架内再狭窄(ISR)患者无心绞痛症状,但此类患者的最佳治疗方案仍不明确。

假设

对于无症状的中度非重度ISR患者,延迟干预可能是安全的,且与良好的临床结局相关。

方法

我们评估了延迟干预后无症状的中度非重度ISR(直径狭窄<70%)患者(第1组,n = 98)的长期临床结局,并将其与无再狭窄患者(第2组,n = 655)的结局进行比较。在延迟重复血管成形术后,所有患者接受药物治疗,仅在临床复发时才进行血管成形术。

结果

两组患者的基线特征相似。所有患者的临床随访时间为26.3±15.9个月。随访期间有20例患者死亡:第1组1例,第2组19例。随访期间,第1组有3例患者、第2组有11例患者进行了靶病变血管重建(p = 无显著性差异),第1组有2例患者、第2组有27例患者进行了新病变血管重建(p = 无显著性差异)。随访结束时,第1组的无事件生存率(心源性死亡、非致命性心肌梗死、重复血管重建)为86.7±6.1%,第2组为84.8±2.2%(p = 无显著性差异)。主要不良心脏事件仅与糖尿病的存在相关(风险比2.65,95%置信区间[CI] 1.48 - 4.73,p<0.01)。研究结束时,两组接受抗心绞痛药物治疗的患者百分比相似(p = 无显著性差异)。

结论

无症状的中度非重度ISR患者预后良好,临床结局与无ISR患者相似,这表明在这些患者心绞痛复发之前延迟重复血管成形术可能是安全的。